Saturday 17 October 2026
Export MLTX’s income statement to Excel — free account
MoonLake Immunotherapeutics
MLTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 3.45%, free cash flow fell 1.89% and total debt rose 35.6%, each against the same quarter a year earlier.
9.55
0.71
−6.92%
Follow MLTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
8.50 | 9.27 | 8.60 | 12.56 |
Net Debt/EBITDA |
4.34 | 4.96 | 3.74 | 7.20 | |
Debt/Assets |
17.80% | 17.46% | 24.73% | 17.34% | |
Debt/Equity |
0.25 | 0.24 | 0.39 | 0.23 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.94 | 0.95 | 0.90 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(22.34) | (32.69) | (30.86) | (23.43) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.70) | (0.91) | (0.93) | (0.75) | |
Cash per Share |
6.00 | 6.11 | 5.02 | 7.27 | |
Shareholders Equity per Share |
4.60 | 4.72 | 3.56 | 5.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.60 | 4.72 | 3.56 | 5.79 | |
Free Cash Flow |
(44.54) | (58.79) | (66.29) | (55.56) | |
Working Capital |
362.85 | 376.22 | 350.53 | 524.65 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
288.07 | 301.74 | 250.29 | 424.29 | |
| Other line items | |||||
Quick Ratio |
7.95 | 8.77 | 7.89 | 11.98 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.70) | (0.91) | (0.93) | (0.75) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
3.21 | 3.86 | 4.38 | 4.99 | |
Average Payables |
18.00 | 19.27 | 17.69 | 17.06 | |
Average Assets |
466.27 | 451.18 | 455.82 | 517.02 | |
Average Common Equity |
393.35 | 378.94 | 333.30 | 393.07 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates